dc.contributor
Institut Català de la Salut
dc.contributor
[Callejo A, Iranzo P, Diaz N, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Frigola J, Carbonell C, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Marmolejo D] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Felip E] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Callejo Perez, Ana
dc.contributor.author
Iranzo Gómez, Patricia
dc.contributor.author
Diaz-Mejia, Nely
dc.contributor.author
Marmolejo Castañeda, David
dc.contributor.author
Assaf, Juan David
dc.contributor.author
Cedres Perez, Susana
dc.contributor.author
Martínez Marti, Alexandre
dc.contributor.author
Navarro Mendivil, Alejandro
dc.contributor.author
Pardo Aranda, Nuria
dc.contributor.author
Amat, Ramon
dc.contributor.author
Carbonell, Caterina
dc.contributor.author
Frigola Rissech, Joan
dc.contributor.author
Felip Font, Enriqueta
dc.date.issued
2022-03-22T13:50:16Z
dc.date.issued
2022-03-22T13:50:16Z
dc.identifier
Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, et al. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Cancers. 2021 Jul;13(13):3249.
dc.identifier
https://hdl.handle.net/11351/7232
dc.identifier
10.3390/cancers13133249
dc.identifier
000671992400001
dc.description.abstract
Biomarcadores; Eventos adversos relacionados con el sistema inmunitario; Inmunoterapia
dc.description.abstract
Biomarcadors; Esdeveniments adversos relacionats amb el sistema immunitari; Immunoteràpia
dc.description.abstract
Biomarkers; Immune related adverse events; Immunotherapy
dc.description.abstract
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed as biomarkers of ICIs response. We assembled a retrospective cohort of 262 NSCLC patients treated with ICIs, compiled relevant clinicopathological characteristics, and studied their associations with treatment outcome using Cox proportional-hazards survival models. Additionally, we investigated the interrelations between clinicopathological features and devised a method to create a compendium associated with ICIs response by selecting those that provide non-redundant information. In multivariate analyses, ECOG performance status (hazard ratio (HR) 1.37 (95% CI 1.11 to 1.68), p < 0.005), LDH (HR 1.24 (95% CI 1.03 to 1.48), p = 0.02)) and PD-L1 negativity were associated with decreased progression-free survival (PFS) (HR 1.92 (95% CI 1.03 to 3.58), p = 0.04), whereas presentation of immune-related adverse events (irAEs) (HR 0.35 (95% CI 0.22 to 0.55, p < 0.005) or females (HR 0.52 (95% CI 0.33 to 0.80, p < 0.005) had longer PFS. Additionally, numerous clinicopathological indicators were found to be interrelated. Thus, we searched for features that provide non-redundant information, and found the combination of LDH levels, irAEs, and gender to have a better association with ICIs treatment response (cross-validated c-index = 0.66). We concluded that several clinicopathological features showed prognostic value in our real-world cohort. However, some are interrelated, and compendiums of features should therefore consider these interactions. Joint assessment of LDH, irAEs, and gender may be a good prognostic compendium.
dc.description.abstract
None associated with this project.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Cancers;13(13)
dc.relation
https://doi.org/10.3390/cancers13133249
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pulmons - Càncer - Tractament
dc.subject
Medicaments antineoplàstics - Ús terapèutic - Eficàcia
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
